Idiopathic pneumonia syndrome (IPS) is a significant cause of morbidity and mortality post-BMT in humans. In our murine IPS model, lethal pre-BMT conditioning and allogeneic T cells result in the recruitment of host antigen-presenting cells (APC) into the lung by day 3 and then donor T cells by day 7 post-BMT concomitant with development of severe lung dysfunction. CCL2 induction was found in bronchoalveolar lavage fluid (BALF) of these recipients prior to host monocyte influx. The major receptor for CCL2 is CCR2 present on monocytes and this interaction has been shown to play a crucial role in monocyte recruitment in inflammation. To cell influx was lost in CCR2 -/-recipients. In CCR2 -/-mice, this influx was accompanied by elevated levels of CCL20 whose exclusive receptor is CCR6 found on myeloid dendritic cells.
Introduction
Idiopathic pneumonia syndrome (IPS) remains a major complication after bone marrow transplantation (11) . Risk factors for developing IPS are related to the intensity of the conditioning regimen used and the degree of alloreactivity of the donor graft (15) . We have characterized a murine model of IPS caused by the influx of host monocytes and donor T cells into the lungs early post-allogeneic BMT of lethally irradiated mice (30) . Intensifying the pre-BMT conditioning with cyclophosphamide potentiates the development of alloreactive T celldependent IPS. Lung dysfunction in our model presents as reduced specific compliance, decreased total lung capacity and increased wet and dry lung weights. Histologically, IPS is associated with injured alveolar type II (ATII) cells and increased frequencies of cells expressing
B7 ligands (costimulatory for T cells) and the cytolytic protein granzyme B (28,30).
Bronchoalveolar lavage (BAL) fluid of mice with IPS contain elevated levels of inflammatory cytokines as well as other indices of lung injury as evidenced by increased levels of nitrite, lactate dehydrogenase and protein (17) .
We reported that monocyte-and T-cell-attracting chemokines are produced in the lung during the generation of IPS in our model (29) . Induction of CCL2 (MCP-1) was found in BALF of these recipient mice prior to host monocyte recruitment on day 3 post-BMT. CCL2 is produced by numerous cell types including monocytes, epithelial cells, fibroblasts and tumor cells (33) .
Endothelial cells are also major producers of CCL2 in response to inflammatory cytokines (32) .
In murine IPS, the highest levels of CCL2 are produced following allogeneic BMT in a T celldependent manner (29) . In vitro studies have shown that high amounts of CCL2 are produced by LCMP-00154-2003R2 4 antigen presenting cells (APCs) that are effective inducers of T cell responses (34). The major receptor for CCL2 is CCR2 present on monocytes and, in rodent systems, this interaction has been shown to play a crucial role in monocyte/macrophage recruitment in inflammation, autoimmunity and resistance to infectious organisms (16, 20, 21, 24, 35, 38, 39) . In relation to the lung, reduced recruitment of monocytes, decreased Th1 cytokine responses and early death have been seen in rodent models of bacterial-induced allergic airway inflammation, granulomatous lung disease, alloantigen-induced bronchiolitis obliterans, and endotoxin administration, in the presence of neutralizing antibodies to CCL2 and in CCL2 -/-or CCR2
-/-mice (1, 8, 10, 25, 27, 31) .
Our previous findings in murine IPS demonstrated the association of early CCL2 production in the lung followed by monocyte influx and inflammatory cytokine production (29 a conditioning regimen pre-BMT on days -3 and -2. All mice were lethally irradiated on the day before BMT (7.5 Gray TBI) by x-ray at a dose rate of 0.41 Gy/minute as described (3).
Bone Marrow Transplant:
Our BMT protocol has been described previously (2 Lung Weights: Mice were euthanized with sodium pentobarbital and the thoracic cavity partially dissected. Lungs were exsanguinated by perfusion with 1.0 mL saline via the right ventricle of the heart. To minimize the number of mice needed for the study without compromising the data, the right lung (bi-lobed) was used for weight determinations while the left lung was processed for histopathology (see below). For each mouse, the wet weight was taken immediately after right lung removal from the thorax. Lungs were dried overnight to a constant weight at 80 o C following by determination of dry weights. The wet/dry weight ratio was calculated and taken as a measure of the severity of lung injury (37) . No correction for extravascular blood content was used in the calculations.
Pressure-Volume Curves:
Following full heart-lung excision, the lungs were suspended via the trachea and kept moist with saline. Pressure-volume (P-V) curves of air-filled lungs were obtained as previously described (30) . Air was delivered into the lungs via a tracheal cannula in 0.05 mL increments with a syringe while measuring intratracheal pressure with a transducer until 30 cm H 2 O pressure was reached. The volume at this pressure was denoted as the total lung capacity (TLC), assuming the volume of air in the collapsed lungs prior to inflation was negligible (compared to the TLC). Air was then withdrawn in 0.05 mL increments until pressure was atmospheric. This was done 3 times and data procured from the third series. 
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Immunohistochemistry: Cryosections (6µm) were fixed in acetone and immunoperoxidasestained using biotinylated mAbs as described (5) View, CA) with 10,000 events analyzed (determined by forward-and side-scatter).
Statistical Analysis: Survival data were analyzed by life table methods using the Mantel-PetoCox summary of chi-square. Other data were analyzed by ANOVA or student's t-test.
Probability (P) values less than or equal to 0.05 were considered statistically significant.
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Results
Post-BMT lung dysfunction and inflammatory cell recruitment are not decreased in CCL2 /-or CCR2 -/-recipients: In our initial description of mouse IPS post-BMT (30), lung injury was highly correlated with decreased total lung capacity and inflammatory cell influx.
Therefore, we wanted to know whether these parameters were affected by loss of CCL2 or 10 the frequencies of monocytes/macrophages, the cells whose migration is presumed to be dictated by the CCL2/CCR2 pathway, did not decrease, indicating that the APC influx had not been affected. However, CCR2 -/-recipients had elevated numbers of CD11b + cells on day 3-post-BMT of BM alone (i.e. without allogeneic splenocytes) in the lung interstitium compared to pretransplant levels ( Figure 3A , triangles, p=0.004, day 3 time point vs day -3) such that the T-cell dependent increase in macrophages was no longer apparent (see also Figure 4A ). This early, Tcell independent, CD11b+ cell influx was not as dramatic in WT recipients and was not seen in CCL2 -/-recipients until day 7 post-BMT ( Figure 3A) . In non-manipulated CCR2 -/-control mice, there appeared to be increased frequencies of CD11b . Thus, elevated levels of CCL20 may be compensatory for the lack of CCL2 in facilitating host APC recruitment into the lung post-BMT.
Higher levels of both pro-and anti-inflammatory T cell mediators in CCL2 -/-and CCR2
-/-recipients: Since differences in some chemokine levels were found in the lungs of CCL2 -/-and CCR2 -/-recipients, levels of Th1-and Th2-related inflammatory cytokine mediators in BALF and lung protein extracts were measured to ascertain whether changes in cytokines may have been affected. We found an elevated level of IFN in the BALF of CCL2 -/-recipients of allogeneic BM and spleen compared to WT B6 recipients ( Figure 5 ). Therefore, this elevated level of IFN coexisted, in these mice, with an elevated level of CCL21 but was not associated with elevated T cell numbers compared to either WT or CCR2 -/-recipients of allogeneic BM and spleen.
Systemic levels of cytokines and chemokines may also influence the pulmonary vasculature, the ensuing inflammatory milieu, chemokine gradients and the extravasation events post-BMT. Of the panel of cytokines and chemokines measured (listed in methods) in the sera, most were not affected by the lack of CCL2 or CCR2 in the recipient mice on day 7 post-BMT. Besides the expected paucity of CCL2 in the CCL2 -/-mice (as stated above), the exception was IL-10 that was elevated, compared to WT, in the sera of CCL2 -/-and CCR2 -/-mice given BM and allogeneic spleen cells ( Figure 5 , p <0.05). Other Th2 cytokines, such as IL-4 and IL-13, were present at equivalent levels in KO mice compared to WT mice post-BMT despite the fact that CCL2 is considered to be critical for Th2 responses. The elevated post-BMT levels of IL-10 in the KO mice were T cell-dependent, consistent with our previous findings in WT mice (30) .
GVHD-mediated mortality is accelerated in the absence of host CCL2 or its receptor

CCR2:
To determine whether host expression of CCL2 or CCR2 would have an effect on the generation of GVHD (that is associated with IPS), lethally irradiated C57BL/6, CCL2 -/-or CCR2 -/-mice were transplanted with B10.BR BM with or without 5 or 25x10 6 splenocytes. Figure 6A shows that CCL2 -/-recipients of allogeneic splenocytes had an accelerated lethality compared to WT recipients at both spleen cell doses (p<0.04). Similar findings were found with CCR2 -/-mice ( Figure 6B ) and these recipients appeared to be 5 times more sensitive to the GVHD induced by allogeneic T cells since CCR2 -/-recipients of 5x10 6 spleen cells had a mortality rate equivalent to WT B6 mice receiving 25x10 6 splenocytes. GVHD-induced weight loss paralleled the survival data (not shown). Therefore, preclusion of the CCL2/CCR2 pathway does not hinder GVHD. On the contrary, GVHD mortality is accelerated.
Discussion
We demonstrate in this study that the presence of the CCL2/CCR2 pathway is not needed for the induction of early post-BMT-related lung injury. Previous data from our laboratory indicated an induction of CCL2 by resident pulmonary cells post-BMT that preceded the influx of host macrophages. These cells comprise the initial infiltrate into the lung early after BMT and may serve to costimulate alloantigen-reactive donor T cells that enter the lung subsequently. The preferred receptor for CCL2 is CCR2 present on monocytes and this ligand-receptor interaction has been shown to be critical for monocyte recruitment in various rodent models of inflammation. We had therefore reasoned that the use of CCL2 or CCR2 knockout mice as recipients would hinder the influx of these cells. Contrary to what we expected, manifestations of IPS were not ameliorated nor was the cellular influx hindered, most likely due to a compensatory increase of other chemoattractants for host APCs (eg. CCL20).
The paucity of systemic and pulmonary levels of CCL2 in the CCL2 -/-recipients post-BMT confirms our earlier hypothesis that CCL2 is host-derived post-BMT (29) . Since CCL2 production in the lung preceded the influx of host monocytes, we anticipated that mice deficient in CCL2 would exhibit less lung injury post-BMT. This was not the case. Others have also found a minimal role for CCL2 in immune-complex mediated lung injury in rats (9). We did not find a GVHD in a dose-dependent fashion (6, 7). In fact, we observed that deficiency of CCL2 or CCR2
did not ameliorate GVHD, but accelerated mortality and body weight loss. Therefore, preclusion of the CCL2/CCR2 pathway does not hinder GVHD. However, cells other than monocytes can also express CCR2 and it has been recently described that bronchiolar and alveolar epithelial cells express CCR2 receptors that functionally respond to CCL2 resulting in proliferation (13, 14) . Therefore, we suggest that the induction and presence of CCL2 in the lung post-BMT may be an attempt by the host to stimulate epithelial cells to re-epithelialize the alveolar basement membrane and not to recruit monocytes per se. Furthermore, the production of CCL2
by these same cell types post-BMT (29) Figure 3A shows groups receiving allogeneic BM alone. Figure 3B shows groups receiving allogeneic BM plus splenocytes.*p<0.05 vs pre-BMT level. 
